Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
IRAK4 Inhibitor
PF-06426779 is a potent and selective inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4), displaying an IC50 of 0.3 nM. This compound effectively modulates inflammatory signaling pathways and is useful in the study of diseases related to dysregulated immune responses. Researchers can leverage PF-06426779 in experimental settings exploring the roles of IRAK4 in cellular processes and potential therapeutic interventions in inflammation-driven disorders. -
IRAK-4 Inhibitor
IRAK-4 protein kinase inhibitor 2 selectively targets interleukin-1 receptor-associated kinase-4 (IRAK-4) with an IC50 of 4 μM. This inhibitor is instrumental in studying inflammatory and immune-related diseases, offering valuable insights into the mechanisms underlying these conditions. Its effective application in research may lead to better understanding and potential therapeutic developments in immune responses. -
IRAK4 Inhibitor
HS271 is a selective inhibitor of IRAK4, demonstrating potent activity with an IC50 of 7.2 μM. This compound exhibits superior enzymatic and cellular efficacy, making it suitable for studies investigating IRAK4-mediated signaling pathways. HS271’s excellent pharmacokinetic properties further enhance its utility in various biological research applications focused on inflammatory processes and immune response modulation. -
IRAK4 Inhibitor
GNE-2256 is a potent inhibitor of IRAK4 (Interleukin 1 receptor associated kinase 4) with a Ki of 1.4 nM, demonstrating high selectivity for this target. It effectively reduces IL-6 production with an IC50 of 190 nM, making it a valuable tool for investigating inflammatory responses and signaling pathways. GNE-2256 is suitable for studies involving autoimmune diseases and other conditions related to aberrant IL-6 signaling. -
IRAK Inhibitor
IRAK inhibitor 4 (trans) is a selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). This compound has demonstrated significant efficacy in blocking IRAK4 activation, thereby modulating the downstream signaling pathways involved in inflammatory responses. It is widely used in research applications focusing on inflammatory disorders and signaling pathways associated with innate immunity. -
IRAK4 Inhibitor
IRAK4-IN-8 is a potent inhibitor of IRAK4, an essential kinase in the interleukin-1 receptor (IL-1R) and Toll-like receptor (TLR) signaling pathways. By selectively inhibiting IRAK4, it modulates downstream inflammatory responses, making it a valuable tool for studying immune pathways. Its primary applications include research on autoimmune disorders, cancer immunotherapy, and the development of novel anti-inflammatory drugs. -
IRAK4 Inhibitor
IRAK4-IN-18 is a selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), exhibiting an IC50 value of 15 nM. This compound is effective in inhibiting lipopolysaccharide (LPS)-induced interleukin-23 (IL-23) production in THP-1 and dendritic cells, demonstrating its potential to modulate inflammatory responses. IRAK4-IN-18 is applicable for research into arthritis and related inflammatory diseases. -
IRAK1/4/pan-FLT3 Inhibitor
IRAK1/4/pan-FLT3 Kinase-IN-2 is a dual inhibitor targeting IRAK1, IRAK4, and FLT3 with IC50 values of 10 nM, 0.7 nM, and <0.5 nM, respectively. This compound demonstrates significant biological activity by extending survival in acute myeloid leukemia model mice. It serves as a valuable tool for research in hematological malignancies and associated therapeutic pathways, facilitating studies on the modulation of kinase activity in cancer. -
IRAK4 Inhibitor
IRAK4-IN-16 is a potent inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4), displaying an IC50 value of 2.5 nM. This compound demonstrates significant cytotoxic effects against various lymphoma cell lines, including OCI-LY10, TMD8, Ramos, and HT, with respective IC50 values of 0.2 μM, 0.2 μM, 0.6 μM, and 2.7 μM. IRAK4-IN-16 is valuable for research in the mechanisms of inflammation and cancer therapy, particularly in targeting IRAK4-related pathways. -
IRAK4 Inhibitor
IRAK4-IN-9 is a potent inhibitor of IRAK4, demonstrating an IC50 of 1.5 nM. This compound effectively disrupts MyD88-dependent signaling pathways, making it a valuable tool for investigating mechanisms of inflammation and immune response. IRAK4-IN-9 is relevant for research applications in inflammatory diseases, autoimmune disorders, and cancer biology. -
IRAK4 Inhibitor
IRAK4-IN-10 is a potent inhibitor of IRAK4, exhibiting an IC50 value of 1.5 nM. This compound effectively interrupts MyD88-dependent signaling pathways, making it a valuable tool for studying the molecular mechanisms underlying inflammatory and autoimmune diseases, as well as various cancers. Its ability to target IRAK4 positions IRAK4-IN-10 as a promising reagent for research in related therapeutic fields. -
IRAK4 Inhibitor
IRAK4-IN-13 is a potent and selective inhibitor of IRAK4 with an IC50 of 0.6 nM. This compound demonstrates significant metabolic clearance, with an intrinsic clearance rate of 96 µL/min/mg in human liver microsomes. IRAK4-IN-13 is useful for studying IRAK4-mediated signaling pathways and evaluating therapeutic strategies in various inflammatory diseases. -
IRAK4 Inhibitor
IRAK4-IN-31 is a selective inhibitor of IRAK4, a key kinase in the Toll-like receptor signaling pathway. This compound exhibits potent inhibitory activity against IRAK4, making it valuable for studying immune signaling and associated pathways. IRAK4-IN-31 is particularly relevant in research related to myelodysplastic syndromes (MDS) and may aid in elucidating therapeutic strategies for hematological malignancies. -
IRAK4 Inhibitor
DW18134 is a selective inhibitor of interleukin receptor-associated kinase 4 (IRAK4) with an IC50 of 11.2 nM. It effectively inhibits the phosphorylation of IRAK4 and IKK, leading to downregulated secretion of pro-inflammatory cytokines TNF-α and IL-6. In preclinical studies, DW18134 demonstrates efficacy in mitigating lipopolysaccharide-induced peritonitis and dextran sulfate sodium-induced colitis in mouse models, while also preserving intestinal barrier integrity. This compound is valuable for researching inflammatory pathways and therapeutic strategies in inflammatory bowel disease. -
IRAK4 Inhibitor
BIO-8169 is a selective inhibitor of interleukin receptor-associated kinase 4 (IRAK4) with an IC50 of 0.23 nM. This compound demonstrates significant anti-inflammatory activity by reducing the production of pro-inflammatory cytokines. Additionally, BIO-8169 shows promising pharmacokinetic properties, including effective blood-brain barrier penetration, indicated by a rat Kpu,u of 0.7, making it suitable for investigating autoimmune conditions such as experimental autoimmune encephalomyelitis (EAE). -
IRAK4 Inhibitor
IRAK4-IN-28 is a potent inhibitor of IRAK4, exhibiting an IC50 of 8.9 nM and a binding affinity characterized by a Kd of 0.58 nM. This compound is suitable for studies targeting inflammation and autoimmune diseases, providing valuable insights into the mechanisms of immune response modulation. Its selectivity and potency make it a useful tool for elucidating the role of IRAK4 in various biological processes. -
IRAK4 Inhibitor
IRAK4-IN-15 is a selective inhibitor of IRAK4, demonstrating a remarkable IC50 of 0.002 µM. This compound exhibits favorable pharmacokinetic predictions in humans with low intrinsic clearance. In vitro studies reveal its potent synergistic activity against MyD88/CD79 double mutant ABC-DLBCL, particularly when used in combination with Acalabrutinib, positioning IRAK4-IN-15 as a valuable tool in cancer research. -
IRAK4 Inhibitor
IRAK4-IN-30 is a potent inhibitor of IRAK4, with an IC50 of 0.6 nM. This compound effectively modulates the signaling pathways associated with the innate immune response. It is valuable for research applications focused on inflammation, autoimmunity, and cancer, providing insights into the mechanistic roles of IRAK4 in various biological processes. -
IRAK4 Inhibitor
IRAK4-IN-17 is a potent inhibitor of IRAK4, exhibiting an IC50 of 1.3 nM. This compound is instrumental for research involving diffuse large B-cell lymphoma (DLBCL), providing insight into the role of IRAK4 in oncogenic signaling pathways. Its high specificity and efficacy make it a valuable tool for investigating therapeutic strategies targeting IRAK4-related mechanisms in cancer biology. -
IRAK4 Inhibitor
ND-2158 is a competitive inhibitor of IRAK4, exhibiting a Ki value of 1.3 nM. This compound effectively suppresses LPS-induced TNF production in human white blood cells and demonstrates therapeutic potential by alleviating collagen-induced arthritis and preventing gout formation in mouse models. Additionally, ND-2158 shows antitumor activity in vivo, making it a valuable tool for research in inflammation and cancer biology. -
IRAK4 Inhibitor
IRAK4-IN-11 is a selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), demonstrating a potent inhibition profile with an IC50 of 0.008 µM. This compound effectively suppresses phosphorylated IRAK4 with an IC50 of 0.19 µM, making it a valuable tool for studying the IL-1 signaling pathway. IRAK4-IN-11 is suitable for research applications focused on inflammation, immune response, and related therapeutic areas. -
IRAK4 Inhibitor
IRAK4-IN-19 is a potent inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), with an IC50 value of 4.3 nM. This compound effectively inhibits lipopolysaccharide (LPS)-induced IL-23 production in THP-1 and dendritic cells, demonstrating its ability to influence inflammatory pathways. IRAK4-IN-19 is valuable for research focused on arthritis and other inflammatory diseases, as it has shown efficacy in preventing the development of arthritis in animal models. -
IRAK4 Type II Inhibitor
HG-12-6 is a type II inhibitor of IRAK4, exhibiting preferential binding to unphosphorylated inactive IRAK4 with an IC50 of 165 nM. This compound effectively modulates IRAK4 activity, making it a valuable tool for studying its role in autoimmunity and inflammation. Researchers can utilize HG-12-6 to investigate pathways associated with immune responses and inflammatory disorders. -
IRAK Inhibitor
IRAK4-IN-25 is a potent inhibitor of IRAK4, with an IC50 of 7.3 nM, demonstrating significant oral bioavailability and low clearance (Cl=12 mL/min/kg). This compound effectively inhibits the production of pro-inflammatory cytokines, making it a valuable tool for studying inflammatory and autoimmune disorders. Its in vitro safety and ADME profiles further support its potential applications in research aimed at understanding immune response modulation. -
IRAK4 Inhibitor
IRAK4-IN-24 is a potent inhibitor of IRAK4, a key kinase involved in the signaling pathways of inflammatory responses. This compound demonstrates significant biological activity, particularly in models of inflammatory and autoimmune disorders. IRAK4-IN-24 facilitates research into the modulation of immune responses and provides insights into potential therapeutic strategies targeting IRAK4 in various disease contexts. -
IRAK4 Inhibitor
IRAK4-IN-26 is a potent inhibitor of IRAK4 with an IC50 of 6.2 nM. This compound exhibits an oral bioavailability of 21%, making it suitable for in vivo studies. IRAK4-IN-26 is valuable for research into inflammatory and autoimmune disorders, facilitating the exploration of therapeutic strategies targeting IRAK4 signaling pathways. -
IRAK4 Inhibitor
BMS-978299 is a selective inhibitor of IRAK4, a critical kinase in the Toll-like receptor (TLR) signaling pathway. This compound demonstrates potent activity in modulating immune response and inflammation, making it a valuable tool for investigating immune disorders and related therapeutic interventions. Researchers can utilize BMS-978299 to further understand the role of IRAK4 in various pathophysiological conditions and to explore potential treatment strategies for immune-related diseases. -
IRAK4 Inhibitor
IRAK4-IN-34 is a potent and selective inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4), exhibiting an IC50 of 0.73 nM. This compound demonstrates significant selectivity against hERG and other kinase targets. With favorable pharmacokinetic properties for in vivo applications, IRAK4-IN-34 is valuable for research into inflammatory diseases and related pathways. -
IRAK4 Inhibitor
ND-2110 is a selective inhibitor of IRAK4, exhibiting a binding affinity with a Ki of 7.5 nM. It effectively targets the ATP binding site of IRAK4 and demonstrates significant biological activity in activated B cell-like (ABC) subtype diffuse large B cell lymphoma (DLBCL) cell lines harboring MYD88 L265P mutations. ND-2110 has been shown to inhibit LPS-induced TNF production and demonstrates therapeutic potential in mouse models of collagen-induced arthritis and gout. -
Src tyrosine kinase inhibitor
Src Inhibitor 1 is a potent and selective dual site Src tyrosine kinase inhibitor with IC50 values of 44 nM for Src and 88nM for Lck. -
ABL/c-KIT dual kinase inhibitor
CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor. -
CSF-1R Inhibitor
GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1. -
multi-targeted tyrosine kinase inhibitor
Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC50s of 4, 20, 4, 2 nM for KDR, Flt-1, FGFR1 and PDGFRα, respectively. -
c-Met inhibitor
c-met-IN-1 (compound 16) is a potent and selective c-Met inhibitor, with IC50 of 1.1 nM, with antitumor activity. -
Eph receptor inhibitor
ALW-II-41-27 is a novel Eph receptor tyrosine kinase inhibitor. -
EGFR inhibitor
CHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant kinase, with IC50s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively. -
PKC inhibitor
PKC 412 is a broad spectrum protein kinase inhibitor. Inhibits conventional PKC isoforms α/β/γ, PDFRβ, VEGFR2, Syk, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1 and EGFR. Displays potent antitumor activity. -
CSF1R inhibitor
JNJ-28312141 is an orally active CSF1R inhibitor (Colony-stimulating factor-1 receptor, CRF1R) and also a FLT3 inhibitor. CSF1R is expressed by many tumors and is a growth factor for macrophages and mediates osteoclast differentiation. JNJ-28312141 represents a new agent with potential therapeutic activity in acute myeloid leukemia and in settings where CSF-1-dependent macrophages and osteoclasts contribute to tumor growth and skeletal events. -
VEGFR inhibitor
NVP-BAW2881 is a potent and selective VEGFR inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor) with activity to inhibit chronic and acute skin inflammation. -
Src Inhibitor
PP1 is a potent inhibitor of Src-family tyrosine kinases. Inhibits p56lck and p59fynT (IC50 values are 5 and 6 nM respectively). Displays > 8000-fold selectivity over ZAP-70 and JAK2. Also moderately inhibits p38, CSK, PDGF receptors, RET-derived oncoproteins, c-Kit and Bcr-Abl -
ErbB inhibitor
ARRY-543 is a novel, oral ErbB family inhibitor that, unlike approved ErbB inhibitors, targets all members of the ErbB family, including ErbB3, either directly or indirectly, and has potential advantages in treating tumors that signal through multiple ErbB family members.
